Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
September 2019—Randox launched at the AACC annual meeting the Randox Stroke Biochip, a highly sensitive blood test that complements CT scanning technology to facilitate accurate classification of stroke patients. The test differentiates between ischemic and hemorrhagic stroke, directs the appropriate patient care pathway, and enables rapid thrombolytic therapy.
July 2019—Randox announced FDA 510(k) clearance for its RX Daytona+ clinical chemistry analyzer. The RX Daytona+ test menu includes routine chemistries, specific proteins, lipids, therapeutic drugs, drugs of abuse, antioxidants, and diabetes and is capable of performing emergency stat sampling. The fully automated benchtop analyzer has a combined throughput of 450 tests per hour, including ISE.
May 2018—Randox Laboratories unveiled Vivalytic, a molecular diagnostics platform, with Bosch Healthcare Solutions at the 28th European Congress of Clinical Microbiology and Infectious Diseases, April 21–24, in Madrid.
March 14, 2018—Randox Laboratories and Bosch Healthcare Solutions will unveil Vivalytic, a fully automated molecular diagnostics platform, at the 28th European Congress of Clinical Microbiology and Infectious Diseases, April 21–24, in Madrid. Vivalytic supports end-point PCR, quantitative real-time PCR, melting curve analysis, and microarray technology, enabling singleplex, low-plex, and high multiplex testing on the same device. Depending on the test application, results are available in 30 minutes. “This is transformational for patients and doctors; never before has there been this
July 2017—Randox Quality Control launched a centralized platform for the management of daily quality control activities
May 2017—Randox has launched Acusera 24.7 Live Online 2.0, which is faster than the previous version, has a simplified user interface, and an enhanced user experience. The biggest update to version 2, according to a company statement, is the ability to review peer data in real time, which enhances troubleshooting capabilities and allows labs to identify trends.
February 2014—The FDA has cleared Randox’s Acusera Liquid Assayed Chemistry Premium Plus, a multianalyte control containing 100 commonly used analytes, for use in U.S. laboratories. Randox believes the “super control” will revolutionize quality control in laboratories, saving time and money while ensuring accurate results and patient diagnosis.
November 2014—Randox released a white paper focusing on the importance of quality control in point-of-care testing. The white paper will help laboratories define an appropriate QC procedure for all point-of-care devices.
June 2014—Randox’s Acusera HbA1c received FDA clearance. It is a 100 percent human whole blood, lyophilized control with assayed values provided for high-performance liquid chromatography and a wide range of clinical chemistry analyzers. When reconstituted the control remains stable for four weeks at 2°–8°C. The control is available in levels 1 and 2, and a calibrator is also available.
Randox Laboratories and Aterovax have announced a strategic partnership to commercialize Aterovax’s secreted phospholipase A2 (sPLA2) biomarker for the assessment of cardiovascular risk.
